Anzeige
Mehr »
Donnerstag, 09.07.2026 - Börsentäglich über 12.000 News
Paukenschlag! Diese Gratis-Aktien könnten jetzt Gold wert sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XDTV | ISIN: NL0010696654 | Ticker-Symbol: UQ1
Tradegate
09.07.26 | 11:13
38,250 Euro
+0,53 % +0,200
1-Jahres-Chart
UNIQURE NV Chart 1 Jahr
5-Tage-Chart
UNIQURE NV 5-Tage-Chart
RealtimeGeldBriefZeit
37,90038,20012:54
37,90038,20012:54

Aktuelle News zur UNIQURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.07.uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?5
29.06.uniQure Closes Upsized $259 Million Public Offering4
25.06.uniQure closes $259M public offering at $45.50 per share4
25.06.uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares481LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...
► Artikel lesen
25.06.Mizuho raises uniQure stock price target to $68 on FDA meeting optimism6
UNIQURE Aktie jetzt für 0€ handeln
24.06.uniQure N.V. - 8-K, Current Report2
24.06.What's next in line for FDA reversals after UniQure and Regenxbio2
24.06.uniQure prices upsized $225M public offering of ordinary shares1
24.06.uniQure prices $225M public offering at $45.50 per share2
24.06.uniQure Inc.: uniQure Announces Pricing of Upsized $225 Million Public Offering731LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...
► Artikel lesen
22.06.uniQure kündigt öffentliches Aktienangebot über 150 Millionen US-Dollar an9
22.06.uniQure files $150M proposed public offering of ordinary shares4
22.06.uniQure Inc.: uniQure Announces $150 Million Proposed Public Offering780LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...
► Artikel lesen
22.06.uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy12
19.06.uniQure reports mixed results from epilepsy gene therapy trial5
19.06.uniQure legt gemischte Studienergebnisse zur Epilepsie-Gentherapie vor6
19.06.uniQure Inc.: uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy527~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~ LEXINGTON, Mass. and AMSTERDAM, June 19...
► Artikel lesen
19.06.uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy2
18.06.uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting1
18.06.UniQure to seek approval of Huntington's gene therapy after FDA U-turn2
Weiter >>
148 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2